Fenwick & West represented DexCom Inc. (NASDAQ:DXCM), a leading provider of continuous glucose monitoring (CGM) systems, in its partnership with Ypsomed (SWX:YPSN), a leading developer and manufacturer of injection and infusion systems for self-medication, to drive development of a hybrid closed loop system.
The partnership is an important milestone in the further development of individualized diabetes therapy. In a first step, CGM data from Dexcom will be integrated into the mylife™ App from Ypsomed. Users of Dexcom CGM and the mylife™ YpsoPump® insulin pump will have all therapy-relevant data in the mylife™ App on their smartphone. View Ypsomed’s announcement to learn more about the company’s partnership with Dexcom.
The Fenwick transaction team was led by technology transactions partner Stefano Quintini and counsel Claire O’Callaghan.